Due to limited effective interventions, the FDA granted EUA for convalescent plasma in August 2020, involving the use of recovered COVID-19 patients blood plasma to treat current infections, particularly effective as a preventive measure or early in symptom onset [16]
In this review, I look at whether Peak Wellness does enough to avoid the Price-Safety Trap by examining pricing, medical oversight, how the program works, and who it is best suited for
Lack of human data means providers typically apply a precautionary principle: avoid GLP-1 therapy during breastfeeding unless maternal benefit substantially outweighs theoretical infant risk
Semaglutide slows gastric emptying, which prolongs the sensation of fullness after meals
However, at $349-$499, this option remains unaffordable for many patients whose insurance does not cover weight loss medications